Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023
Executive Summary
The report titled “Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023” presents the market potential of six major pipeline drugs meant for the treatment of Psoriasis. These six drugs that fall in the various categories of Injectables, Oral pills and Topical creams/lotions by mode of administration have been recognized as being clinically effective in Psoriasis treatment. Expected to be launched in the market within the next 4-5 years, these six potential drugs are likely to bring about major changes in the way psoriasis is treated globally.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Psoriasis Pipeline Drugs Market by assessing the potential of the six drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the six drugs, the product profile, description and regulatory phase of each of the six drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the six drugs to present the current perspective.
Over the recent years, the Psoriasis Drugs market is growing rapidly due to rising prevalence of Psoriasis patients around the world. Globally, the growth of Psoriasis Drugs market is driven by rising psoriatic population. The global psoriasis drugs market is projected to display a robust growth during 2019– 2023, chiefly driven by low efficacy and tolerability of present psoriasis drugs and improved safety and efficacy of investigational drugs.
The report has covered and analysed the major psoriasis drugs that are in pipeline and expected to be launched in the near future. The product profile, assessment of clinical trials, the regulatory phases and the potential of the drugs has been analysed in the report. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decision. The report titled “Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023” also analyzes the incidences of psoriasis in countries like United States, United Kingdom, France, Italy, Spain, Germany and Norway.
Scope of the Report
Psoriasis Pipeline Drugs Assessment – Drug X1, X2, X3, X4, X5, X6 (Forecast Period: 2019-2023)
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
The report titled “Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023” presents the market potential of six major pipeline drugs meant for the treatment of Psoriasis. These six drugs that fall in the various categories of Injectables, Oral pills and Topical creams/lotions by mode of administration have been recognized as being clinically effective in Psoriasis treatment. Expected to be launched in the market within the next 4-5 years, these six potential drugs are likely to bring about major changes in the way psoriasis is treated globally.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Psoriasis Pipeline Drugs Market by assessing the potential of the six drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the six drugs, the product profile, description and regulatory phase of each of the six drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the six drugs to present the current perspective.
Over the recent years, the Psoriasis Drugs market is growing rapidly due to rising prevalence of Psoriasis patients around the world. Globally, the growth of Psoriasis Drugs market is driven by rising psoriatic population. The global psoriasis drugs market is projected to display a robust growth during 2019– 2023, chiefly driven by low efficacy and tolerability of present psoriasis drugs and improved safety and efficacy of investigational drugs.
The report has covered and analysed the major psoriasis drugs that are in pipeline and expected to be launched in the near future. The product profile, assessment of clinical trials, the regulatory phases and the potential of the drugs has been analysed in the report. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decision. The report titled “Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023” also analyzes the incidences of psoriasis in countries like United States, United Kingdom, France, Italy, Spain, Germany and Norway.
Scope of the Report
Psoriasis Pipeline Drugs Assessment – Drug X1, X2, X3, X4, X5, X6 (Forecast Period: 2019-2023)
- Market Potential
- Clinical Trials
- Product Description
- Regulatory Phases
- 7Ps Analysis
- Incidence of Psoriasis
- Company Analysis – UCB, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim, Forward Pharma, Almirall and Valeant Pharmaceuticals
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
1. RESEARCH METHODOLOGY
2. PSORIASIS - AN OVERVIEW
2.1. Symptoms of Psoriasis
2.2. Types of Psoriasis
2.3. Causes of Psoriasis
2.4. Triggers, Risk Factors and Complications of Psoriasis
3. DIAGNOSIS OF PSORIASIS
4. TREATMENT OF PSORIASIS
5. ANTI-PSORIASIS PIPELINE DRUGS
5.1. Anti-Psoriasis Pipeline Drugs – Cimzia (Certolizumab Pegol)
5.1.1. Description
5.1.2. Regulatory Milestones
5.1.3. Advantages & Disadvantages
5.1.4. Product Profile & Launch Date
5.1.5. Clinical Trials and Status
5.1.6. Pivotal Clinical Trials and Results
5.1.7. Cimzia (Certolizumab Pegol) – Global Market Potential
5.1.8. Cimzia (Certolizumab Pegol) – 7Ps Analysis
5.2. Anti-Psoriasis Pipeline Drugs – Tildrakizumab (MK-3222)
5.2.1. Description
5.2.2. Regulatory Milestones
5.2.3. Advantages & Disadvantages
5.2.4. Product Profile & Launch Date
5.2.5. Clinical Trials and Status
5.2.6. Pivotal Clinical Trials and Results
5.2.7. Tildrakizumab (MK-3222)– Global Market Potential
5.2.8. Tildrakizumab (MK-3222)– 7Ps Analysis
5.3. Anti-Psoriasis Pipeline Drugs – Risankizumab (BI 655066)
5.3.1. Description
5.3.2. Regulatory Milestones
5.3.3. Advantages & Disadvantages
5.3.4. Product Profile & Launch Date
5.3.5. Clinical Trials and Status
5.3.6. Pivotal Clinical Trials and Results
5.3.7. Risankizumab (BI 655066)– Global Market Potential
5.3.8. Risankizumab (BI 655066)– 7Ps Analysis
5.4. Anti-Psoriasis Pipeline Drugs – FP187
5.4.1. Description
5.4.2. Regulatory Milestones
5.4.3. Advantages & Disadvantages
5.4.4. Product Profile & Launch Date
5.4.5. Clinical Trials and Status
5.4.6. Pivotal Clinical Trials and Results
5.4.7. FP187 – Global Market Potential
5.4.8. FP187 – 7Ps Analysis
5.5. Anti-Psoriasis Pipeline Drugs – Skilarence (LAS41008)
5.5.1. Description
5.5.2. Regulatory Milestones
5.5.3. Advantages & Disadvantages
5.5.4. Product Profile & Launch Date
5.5.5. Clinical Trials and Status
5.5.6. Pivotal Clinical Trials and Results
5.5.7. Skilarence (LAS41008) – Global Market Potential
5.5.8. Skilarence (LAS41008) – 7Ps Analysis
5.6. Anti-Psoriasis Pipeline Drugs – Duobrii (IDB 118)
5.6.1. Description
5.6.2. Regulatory Milestones
5.6.3. Advantages & Disadvantages
5.6.4. Product Profile & Launch Date
5.6.5. Clinical Trials and Status
5.6.6. Pivotal Clinical Trials and Results
5.6.7. Duobrii (IDB 118) – Global Market Potential
5.6.8. Duobrii (IDB 118) – 7Ps Analysis
6. COMPANY PROFILES
6.1. UCB
6.2. Sun Pharmaceutical Industries Ltd
6.3. Boehringer Ingelheim
6.4. Forward Pharma
6.5. Almirall
6.6. Valeant Pharmaceuticals
7. NUMBER OF PSORIASIS PATIENTS BY COUNTRY
7.1. U.S
7.2. U.K
7.3. France
7.4. Italy
7.5. Germany
7.6. Norway
2. PSORIASIS - AN OVERVIEW
2.1. Symptoms of Psoriasis
2.2. Types of Psoriasis
2.3. Causes of Psoriasis
2.4. Triggers, Risk Factors and Complications of Psoriasis
3. DIAGNOSIS OF PSORIASIS
4. TREATMENT OF PSORIASIS
5. ANTI-PSORIASIS PIPELINE DRUGS
5.1. Anti-Psoriasis Pipeline Drugs – Cimzia (Certolizumab Pegol)
5.1.1. Description
5.1.2. Regulatory Milestones
5.1.3. Advantages & Disadvantages
5.1.4. Product Profile & Launch Date
5.1.5. Clinical Trials and Status
5.1.6. Pivotal Clinical Trials and Results
5.1.7. Cimzia (Certolizumab Pegol) – Global Market Potential
5.1.8. Cimzia (Certolizumab Pegol) – 7Ps Analysis
5.2. Anti-Psoriasis Pipeline Drugs – Tildrakizumab (MK-3222)
5.2.1. Description
5.2.2. Regulatory Milestones
5.2.3. Advantages & Disadvantages
5.2.4. Product Profile & Launch Date
5.2.5. Clinical Trials and Status
5.2.6. Pivotal Clinical Trials and Results
5.2.7. Tildrakizumab (MK-3222)– Global Market Potential
5.2.8. Tildrakizumab (MK-3222)– 7Ps Analysis
5.3. Anti-Psoriasis Pipeline Drugs – Risankizumab (BI 655066)
5.3.1. Description
5.3.2. Regulatory Milestones
5.3.3. Advantages & Disadvantages
5.3.4. Product Profile & Launch Date
5.3.5. Clinical Trials and Status
5.3.6. Pivotal Clinical Trials and Results
5.3.7. Risankizumab (BI 655066)– Global Market Potential
5.3.8. Risankizumab (BI 655066)– 7Ps Analysis
5.4. Anti-Psoriasis Pipeline Drugs – FP187
5.4.1. Description
5.4.2. Regulatory Milestones
5.4.3. Advantages & Disadvantages
5.4.4. Product Profile & Launch Date
5.4.5. Clinical Trials and Status
5.4.6. Pivotal Clinical Trials and Results
5.4.7. FP187 – Global Market Potential
5.4.8. FP187 – 7Ps Analysis
5.5. Anti-Psoriasis Pipeline Drugs – Skilarence (LAS41008)
5.5.1. Description
5.5.2. Regulatory Milestones
5.5.3. Advantages & Disadvantages
5.5.4. Product Profile & Launch Date
5.5.5. Clinical Trials and Status
5.5.6. Pivotal Clinical Trials and Results
5.5.7. Skilarence (LAS41008) – Global Market Potential
5.5.8. Skilarence (LAS41008) – 7Ps Analysis
5.6. Anti-Psoriasis Pipeline Drugs – Duobrii (IDB 118)
5.6.1. Description
5.6.2. Regulatory Milestones
5.6.3. Advantages & Disadvantages
5.6.4. Product Profile & Launch Date
5.6.5. Clinical Trials and Status
5.6.6. Pivotal Clinical Trials and Results
5.6.7. Duobrii (IDB 118) – Global Market Potential
5.6.8. Duobrii (IDB 118) – 7Ps Analysis
6. COMPANY PROFILES
6.1. UCB
6.2. Sun Pharmaceutical Industries Ltd
6.3. Boehringer Ingelheim
6.4. Forward Pharma
6.5. Almirall
6.6. Valeant Pharmaceuticals
7. NUMBER OF PSORIASIS PATIENTS BY COUNTRY
7.1. U.S
7.2. U.K
7.3. France
7.4. Italy
7.5. Germany
7.6. Norway
LIST OF FIGURES
Figure 1: Response rate of patients who achieved PASI at week 16 in CIMPASI-1 & CIMPASI-2
Figure 2: Rate of patients achieving at least a two-point improvement to a final score of clearance or almost clear skin on PGA Scale at week 16 in CIMPASI-1 & CIMPASI-2
Figure 3: Response rate of patients who achieved PASI 75 at week 12 in CIMPACT
Figure 4: Response rate of patients who achieved PASI 75 at week 16 in CIMPACT
Figure 5: Response Rate of patients achieving at least a two-point improvement to a final score of clearance or almost clear skin on PGA Scale at week 16 in CIMPACT
Figure 6: Global Cimzia Market Size, By Value, Forecast, 2019-2023 (USD million)
Figure 7: Response rate of patients in 100mg dose regimen
Figure 8: Response rate of patients in 200mg dose regimen
Figure 9: Global Tildrakizumab (MK-3222) Market Size, By Value, Forecast, 2019-2023 (USD million)
Figure 10: Response rate of patients in ultiMMa-1 (at wee 16)
Figure 11: Response rate of patients in ultiMMa-2 (at week 16)
Figure 12: Response rate of patients in ultiMMa-1 (at 1 year)
Figure 13: Response rate of patients in ultiMMa-2 (at 1 year)
Figure 14: Response rate of patients in IMMvent (at week 16)
Figure 15: Response rate of patients in IMMhance (at week 16)
Figure 16: Global Risankizumab (BI 655066) Market Size, By Value, Forecast, 2019-2023 (USD million)
Figure 17: Percent of Patients achieving PASI75 in 500mg dose arm (at week 20)
Figure 18: Percent of Patients achieving PASI75 in 750mg dose arm (at week 20)
Figure 19: Percent of Patients achieving PASI75 open label up-titration treatment arm, 750mg dose (at week 20)
Figure 20: FP-187 Market Size, By Value, Forecast, 2019-2023 (USD million)
Figure 21: Response rate of patients achieving PASI 75 at week
Figure 22: Global Skilarence (LAS41008) Market Size, By Value, Forecast, 2021-2023 (USD million)
Figure 23: Percentage of success (IGA 0/1) at week
Figure 24: Global IDP-118 Market Size, By Value, Forecast, 2019-2023 (USD million)
Figure 25: UCB Company Revenues, By Value, in million USD
Figure 26: UCB net sales, by value, in million USD
Figure 27: UCB net sales by geography, by value, in million USD
Figure 28: UCB net sales in 2016, by geography
Figure 29: Number of Psoriasis Patients in U.S, 2012-2016 (in million)
Figure 30: Number of Psoriasis Patients in U.K, 2012-2016 (in million)
Figure 31: Number of Psoriasis Patients in France, 2012-2016 (in million)
Figure 32: Number of Psoriasis Patients in Italy, 2012-2016 (in million)
Figure 33: Number of Psoriasis Patients in Germany, 2012-2016 (in million)
Figure 34: Number of Psoriasis Patients in Norway, 2012-2016 (in million)
Figure 1: Response rate of patients who achieved PASI at week 16 in CIMPASI-1 & CIMPASI-2
Figure 2: Rate of patients achieving at least a two-point improvement to a final score of clearance or almost clear skin on PGA Scale at week 16 in CIMPASI-1 & CIMPASI-2
Figure 3: Response rate of patients who achieved PASI 75 at week 12 in CIMPACT
Figure 4: Response rate of patients who achieved PASI 75 at week 16 in CIMPACT
Figure 5: Response Rate of patients achieving at least a two-point improvement to a final score of clearance or almost clear skin on PGA Scale at week 16 in CIMPACT
Figure 6: Global Cimzia Market Size, By Value, Forecast, 2019-2023 (USD million)
Figure 7: Response rate of patients in 100mg dose regimen
Figure 8: Response rate of patients in 200mg dose regimen
Figure 9: Global Tildrakizumab (MK-3222) Market Size, By Value, Forecast, 2019-2023 (USD million)
Figure 10: Response rate of patients in ultiMMa-1 (at wee 16)
Figure 11: Response rate of patients in ultiMMa-2 (at week 16)
Figure 12: Response rate of patients in ultiMMa-1 (at 1 year)
Figure 13: Response rate of patients in ultiMMa-2 (at 1 year)
Figure 14: Response rate of patients in IMMvent (at week 16)
Figure 15: Response rate of patients in IMMhance (at week 16)
Figure 16: Global Risankizumab (BI 655066) Market Size, By Value, Forecast, 2019-2023 (USD million)
Figure 17: Percent of Patients achieving PASI75 in 500mg dose arm (at week 20)
Figure 18: Percent of Patients achieving PASI75 in 750mg dose arm (at week 20)
Figure 19: Percent of Patients achieving PASI75 open label up-titration treatment arm, 750mg dose (at week 20)
Figure 20: FP-187 Market Size, By Value, Forecast, 2019-2023 (USD million)
Figure 21: Response rate of patients achieving PASI 75 at week
Figure 22: Global Skilarence (LAS41008) Market Size, By Value, Forecast, 2021-2023 (USD million)
Figure 23: Percentage of success (IGA 0/1) at week
Figure 24: Global IDP-118 Market Size, By Value, Forecast, 2019-2023 (USD million)
Figure 25: UCB Company Revenues, By Value, in million USD
Figure 26: UCB net sales, by value, in million USD
Figure 27: UCB net sales by geography, by value, in million USD
Figure 28: UCB net sales in 2016, by geography
Figure 29: Number of Psoriasis Patients in U.S, 2012-2016 (in million)
Figure 30: Number of Psoriasis Patients in U.K, 2012-2016 (in million)
Figure 31: Number of Psoriasis Patients in France, 2012-2016 (in million)
Figure 32: Number of Psoriasis Patients in Italy, 2012-2016 (in million)
Figure 33: Number of Psoriasis Patients in Germany, 2012-2016 (in million)
Figure 34: Number of Psoriasis Patients in Norway, 2012-2016 (in million)
